Structure-Based Design
of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based
Derivatives
- Publication date
- Publisher
Abstract
Deregulation of c-Met receptor tyrosine kinase activity
leads to
tumorigenesis and metastasis in animal models. More importantly, the
identification of activating mutations in c-Met, as well as <i>MET</i> gene amplification in human cancers, points to c-Met
as an important target for cancer therapy. We have previously described
two classes of c-Met kinase inhibitors (class I and class II) that
differ in their binding modes and selectivity profiles. The class
II inhibitors tend to have activities on multiple kinases. Knowledge
of the binding mode of these molecules in the c-Met protein led to
the design and evaluation of several new class II c-Met inhibitors
that utilize various 5-membered cyclic carboxamides to conformationally
restrain key pharmacophoric groups within the molecule. These investigations
resulted in the identification of a potent and novel class of pyrazolone
c-Met inhibitors with good in vivo activity